Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. has announced a strategic commercial agreement with Maccabi Healthcare Services, Israel’s second-largest HMO serving over 2.8 million patients, marking a pivotal milestone in TempraMed’s global expansion of its temperature-controlled medication protection technologies. The partnership brings TempraMed’s flagship devices, VIVI Cap and VIVI EPI, into one of the world’s most advanced healthcare networks, reinforcing the company’s mission to safeguard the efficacy of temperature-sensitive injectables used in chronic disease management.
Science Significance
The collaboration highlights growing scientific recognition of the critical role temperature stability plays in the biochemical integrity and therapeutic performance of medications such as insulin, GLP-1 injectables, and epinephrine autoinjectors. TempraMed’s devices use a patented combination of deep-vacuum insulation and phase-change materials that maintain a safe thermal range without batteries, refrigeration, or external power, a unique scientific advantage that protects active pharmaceutical ingredients from denaturation. By preventing heat- and cold-related degradation, TempraMed’s technology directly supports medication potency, reliability, and real-world therapeutic outcomes, advancing the scientific standards of portable drug-stability management.
Regulatory Significance
The rollout through a large HMO reflects increasing regulatory attention on medication quality, storage compliance, and continuity of product integrity after dispensing. TempraMed’s FDA-registered products align with regulatory frameworks emphasizing post-market medication handling and patient-managed storage conditions, areas increasingly scrutinized by global regulators as biologics and temperature-sensitive chronic therapies dominate formularies. As more nations enact or update Good Distribution Practice (GDP) and Good Pharmacy Practice (GPP) guidelines, reliable temperature-protection devices strengthen healthcare systems’ ability to ensure compliance across the full medication lifecycle. The partnership sets a precedent for integrating patient-level temperature-control technologies into regulated care pathways.
Business Significance
Advertisement
This strategic agreement marks an inflection point for TempraMed as it scales its commercial footprint, following the sale of over 120,000 units worldwide and distribution through major U.S. retailers including Walgreens, CVS, Walmart, Target, and major medical distributors such as McKesson and Cardinal Health. Access to Maccabi’s large patient base accelerates TempraMed’s entry into institutional healthcare markets, strengthening recurring revenue opportunities through chronic-condition patient populations. With a rapidly expanding product pipeline addressing GLP-1 therapies, biologics, and blood-temperature management, TempraMed positions itself as a future leader in temperature-controlled medtech innovation, advancing toward cashflow positivity and global category leadership.
Patients’ Significance
For millions living with diabetes, anaphylaxis, and other chronic conditions requiring temperature-sensitive medications, this partnership provides direct access to reliable, portable, and maintenance-free temperature protection technology. By ensuring that medications remain within their safe efficacy range during daily routines, travel, outdoor activity, and emergency situations, TempraMed’s devices offer patients greater confidence, safety, and independence. The lightweight, reusable design eliminates reliance on ice packs or power sources, reducing treatment burden and improving adherence to therapy, ultimately supporting better long-term health outcomes.
Policy Significance
As global health systems confront rising demand for biologics, self-injectables, and chronic disease therapies, the need for consistent medication integrity standards beyond the pharmacy is expanding. TempraMed’s collaboration with Maccabi aligns with policy trends that prioritize preventive care, patient empowerment, and technologies that reduce avoidable medication failures. By incorporating temperature-control devices into mainstream care delivery, healthcare institutions can support broader policies aimed at lowering medication wastage, reducing adverse events related to temperature exposure, and improving continuity of care in decentralized treatment models.
TempraMed’s strategic agreement with Maccabi Healthcare Services represents a significant advancement in the global adoption of smart temperature-protection solutions for chronic medications, reinforcing scientific, regulatory, business, and patient-centered priorities across healthcare ecosystems. As the company advances new device formats and future digital integration with real-time tracking and personalized health data, it stands poised to redefine the global standard for medication protection, adherence, and therapeutic reliability in an increasingly temperature-sensitive pharmaceutical landscape.
Source: TempraMed Technologies Ltd. press release
